BLACK BOX WARNING
- severe hypoglycemia, particularly in type 1 diabetes; reduce mealtime insulin by 50% when initiating pramlintide
pramlintide
Brand: Symlin
⚠ BBW Prototype Drug
Drug Class: amylin analog
Drug Family: antidiabetic
Subclass: synthetic amylin analog
Organ Systems: endocrine
Mechanism of Action
Synthetic analog of amylin, a peptide co-secreted with insulin by pancreatic beta cells. Activates amylin receptors in the brainstem and area postrema to suppress postprandial glucagon secretion, slow gastric emptying, and reduce appetite/caloric intake, complementing insulin's effects on postprandial glucose.
amylin receptors (CTR/RAMP complexes)
Indications
- type 1 diabetes mellitus (adjunct to mealtime insulin)
- type 2 diabetes mellitus (adjunct to mealtime insulin)
Contraindications
- hypoglycemia unawareness
- gastroparesis
- hypersensitivity
Adverse Effects
Common
- nausea (30–40%)
- vomiting
- headache
- fatigue
- hypoglycemia (severe — within 3 hours of meal)
Serious
- severe insulin-induced hypoglycemia (pramlintide slows gastric emptying; mealtime insulin peaks while glucose absorption is delayed)
Pharmacokinetics (ADME)
| Absorption | subcutaneous injection; bioavailability ~30–40% |
| Distribution | Vd ~0.54 L/kg |
| Metabolism | renal catabolism |
| Excretion | renal |
| Half-life | 48 minutes |
| Onset | 15 minutes |
| Peak | 19–21 minutes |
| Duration | ~3 hours |
| Protein Binding | ~40% |
| Vd | 0.54 L/kg |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| rapid-acting insulin (mealtime) | additive hypoglycemia; reduce insulin dose by 50% when starting; risk highest within 3 hours post-meal | major |
| agents slowing GI motility | additive gastroparesis effect; contraindicated in gastroparesis | major |
Nursing Considerations
- NEVER MIX pramlintide with insulin in the same syringe — must be injected separately; inject within 2 inches of the insulin injection site.
- Reduce mealtime insulin dose by 50% when initiating pramlintide to prevent severe hypoglycemia; retitrate insulin as needed.
- Closely monitor glucose for 3 hours after injection; severe hypoglycemia typically occurs in this window.
- Administer immediately before major meals; if a meal is skipped, skip pramlintide dose.
Clinical Pearls
- Pramlintide is the only amylin analog approved for clinical use; it targets the 'missing' amylin signal in T1DM (amylin is not produced) and T2DM (amylin secretion declines with progressive beta-cell failure).
- The black box warning of severe hypoglycemia with mealtime insulin is the most important safety concern — the insulin dose reduction protocol at initiation is mandatory.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.